Midbrain dopaminergic (mDA) neurons critically control voluntary movement, reward, and mood-related behaviors, and their degeneration/dysfunction is associated with major brain disorders such as Parkinson's disease (PD) and schizophrenia. Thus, it is critical to understand molecular mechanisms underlying development, survival, and function of mDA neurons in health and disease. During the last funding cycle, we investigated the regulatory networks of key extrinsic factors and intrinsic transcription factors that critically control mDA neuronal development, focusing on the role and regulation of Pitx3. We found that Wnt1-Lmx1a form an autoregulatory pathway leading to induction of key transcription factors, Nurr1 and Pitx3. Notably, these studies revealed that two major pathways controlling mDA neuronal development (i.e., Shh-FoxA2 and Wnt1-Lmx1a) merge on Nurr1, highlighting Nurr1's essential role(s) for mDA neuron development/ maintenance. Indeed, recent studies showed that Nurr1 is critical not only for the development and long-term maintenance of mDA neurons (by transactivation function) but also for their protection from inflammation-induced death (through transrepression of inflammatory genes). Nurr1 is an orphan nuclear receptor and is known as a ligand-independent constitutively active nuclear receptor. Strikingly, however, we recently identified small molecules that can directly interact with the ligand binding domain of Nurr1 stimulating its contrasting dual functions; furthe activating the mDA neuronal function and further transrepressing expression of inflammatory genes in microglia. Based on these promising data identifying potential synthetic ligands/agonists of Nurr1, we hypothesize that Nurr1 may be an adopted nuclear receptor and that there may exist an endogenous Nurr1 ligand. Furthermore, Nurr1's diverse functions (e.g., transactivation, transrepression, or no apparent function) appear to depend upon the cellular context, which may be determined by cell-specific Nurr1-interacting factor(s). To address these hypotheses, we will systematically investigate the contrasting dual functions of Nurr1 in the absence and in the presence of agonist molecules and will identify and characterize multiprotein complexes associated with Nurr1 in different cellular contexts and the putative endogenous ligand(s). Our proposal is highly novel and innovative and will shed new insights into the functional roles of Nurr1 in mDA neurons, potentially leading to a paradigm-shift of our understanding of Nurr1's functional roles on mDA neurobiology and future therapeutic development of DA-related brain disorders.

Public Health Relevance

Midbrain dopamine (mDA) neurons play critical roles in the regulation of voluntary movement, emotion, and reward-related behavior, and their degeneration and/or dysfunction are associated with major brain disorders such as Parkinson's disease (PD), schizophrenia, and drug addiction. Based on our recent data identifying small molecules that can interact with the ligand binding domain of the orphan nuclear receptor Nurr1 leading to its activation, we will systematically investigate the contrasting dual functions of Nurr1 in the absence and in the presence of agonist molecules and identify and characterize the 'putative' endogenous ligand. Our proposal is highly novel and innovative and, if successfully done, will potentially lead to a paradigm shift of our understanding of Nurr1's functional roles on mDA neurobiology and future therapeutic development of DA- related brain disorders.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS084869-23
Application #
8914053
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Sieber, Beth-Anne
Project Start
2014-09-01
Project End
2019-06-30
Budget Start
2015-07-01
Budget End
2016-06-30
Support Year
23
Fiscal Year
2015
Total Cost
Indirect Cost
Name
Mclean Hospital
Department
Type
DUNS #
046514535
City
Belmont
State
MA
Country
United States
Zip Code
Sonntag, Kai-C; Song, Bin; Lee, Nayeon et al. (2018) Pluripotent stem cell-based therapy for Parkinson's disease: Current status and future prospects. Prog Neurobiol 168:1-20
Kim, Kwang-Soo (2017) Toward neuroprotective treatments of Parkinson's disease. Proc Natl Acad Sci U S A 114:3795-3797
Chumarina, Margarita; Azevedo, Carla; Bigarreau, Julie et al. (2017) Derivation of mouse embryonic stem cell lines from tyrosine hydroxylase reporter mice crossed with a human SNCA transgenic mouse model of Parkinson's disease. Stem Cell Res 19:17-20
Cha, Young; Han, Min-Joon; Cha, Hyuk-Jin et al. (2017) Metabolic control of primed human pluripotent stem cell fate and function by the miR-200c-SIRT2 axis. Nat Cell Biol 19:445-456
Moon, Jisook; Schwarz, Sigrid C; Lee, Hyun-Seob et al. (2017) Preclinical Analysis of Fetal Human Mesencephalic Neural Progenitor Cell Lines: Characterization and Safety In Vitro and In Vivo. Stem Cells Transl Med 6:576-588
Han, Baek-Soo; Kim, Kyoung-Shim; Kim, Yu Jin et al. (2016) Daphnane Diterpenes from Daphne genkwa Activate Nurr1 and Have a Neuroprotective Effect in an Animal Model of Parkinson's Disease. J Nat Prod 79:1604-9
Oh, Sera; Shin, Ji Hyun; Jang, Eun Jung et al. (2016) Anti-inflammatory activity of chloroquine and amodiaquine through p21-mediated suppression of T cell proliferation and Th1 cell differentiation. Biochem Biophys Res Commun 474:345-350
Ahn, Sandra; Kim, Tae-Gon; Kim, Kwang-Soo et al. (2016) Differentiation of human pluripotent stem cells into Medial Ganglionic Eminence vs. Caudal Ganglionic Eminence cells. Methods 101:103-12
Kim, Chun-Hyung; Leblanc, Pierre; Kim, Kwang-Soo (2016) 4-amino-7-chloroquinoline derivatives for treating Parkinson's disease: implications for drug discovery. Expert Opin Drug Discov 11:337-41
Leblanc, Pierre; Moon, Minho; Kim, Woori et al. (2015) Production of Nurr-1 Specific Polyclonal Antibodies Free of Cross-reactivity Against Its Close Homologs, Nor1 and Nur77. J Vis Exp :e52963

Showing the most recent 10 out of 13 publications